首頁 › 慢性淋巴性白血病 › 明尼蘇達 › Rochester
Rochester, MN 的 慢性淋巴性白血病 臨床試驗
19 項針對 慢性淋巴性白血病 的研究正在 Rochester（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
招募中2 期
- Mayo Clinic in Rochester, Rochester
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
招募中1/2 期
- Research Site, Rochester
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
招募中3 期
- Mayo Clinic Rochester, Rochester
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
招募中1/2 期
- Mayo Clinic Rochester, Rochester
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
招募中3 期
- Mayo Clinic Rochester, Rochester
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
招募中3 期
- Mayo Clinic Rochester, Rochester
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
招募中1 期
- Mayo Clinic Rochester, Rochester
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
招募中1/2 期
- Mayo Clinic, Rochester
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
招募中1/2 期
- Mayo Clinic, Clinical Trials Referral Office, Rochester
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
招募中2 期
- Mayo Clinic, Rochester
CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies
招募中1 期
- Mayo Clinic in Rochester, Rochester
The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients
招募中歡迎健康志工
- Mayo Clinic in Rochester, Rochester
Hematopoiesis in MBL and CLL Versus Healthy Age-Matched Control Subjects
招募中觀察性研究歡迎健康志工
- Mayo Clinic in Rochester, Rochester
Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
招募中2 期
- Mayo Clinic in Rochester, Rochester
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
招募中4 期
- Mayo Clinic- Minnesota, Rochester
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
招募中4 期
- Mayo Clinic- Minnesota, Rochester
Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
招募中觀察性研究
- Mayo Clinic in Rochester, Rochester
Family Study of Lymphoproliferative Disorders
招募中觀察性研究歡迎健康志工
- Mayo Clinic, Rochester
Q702 for the Treatment of Patients With Hematologic Malignancies
招募中1 期
- Mayo Clinic in Rochester, Rochester
其他城市的 慢性淋巴性白血病 試驗
- Boston, MA31 項研究
- Columbus, OH28 項研究
- Durham, NC27 項研究
- Washington, DC22 項研究
- Seattle, WA20 項研究
- New York City, NY18 項研究
- Houston, TX17 項研究
- Baldwin Park, CA16 項研究
- Milwaukee, WI15 項研究
- Chicago, IL14 項研究
- Cincinnati, OH14 項研究
- Nashville, TN13 項研究
Rochester 的其他研究
- 乳癌42 項研究
- 非小細胞肺癌37 項研究
- 轉移性癌症31 項研究
- 癌症（所有類型）30 項研究
- 大腸直腸癌29 項研究
- 卵巢癌29 項研究
- 多發性骨髓瘤24 項研究
- 前列腺癌22 項研究
- 心臟衰竭22 項研究
- 胰臟癌22 項研究
- 肺癌20 項研究
- 子宮內膜癌20 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月5日。各研究自行設定資格標準；由研究團隊決定參與者資格。